Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Strongyloidiasis

INTRODUCTION

Strongyloidiasis is caused by infection with Strongyloides stercoralis. Manifestations of infection can range from asymptomatic eosinophilia in the immunocompetent host to disseminated disease with septic shock in the immunocompromised host.

EPIDEMIOLOGY

Strongyloidiasis is endemic in tropical and subtropical regions and occurs sporadically in temperate areas. In tropical and subtropical regions the overall regional prevalence may exceed 25 percent. The highest rates of infection in the United States are among residents of the southeastern states [1,2] and among individuals who have been in endemic areas (including immigrants, refugees, travelers and military personnel) [3,4]. Transmission of strongyloidiasis in a long-term care setting has also been described [2].

A Canadian study of newly arrived Southeast Asian refugees identified strongyloidiasis seroprevalence among Kampucheans, Laotians, and Vietnamese (76, 56, and 12 percent, respectively) [4]. In another study, over 40 percent of Cambodian immigrants to Australia had positive or equivocal strongyloides serology indicating possible infection [5].

LIFE CYCLE

The infection begins when human skin contacts filariform larvae (the infective larval stage) of S. stercoralis, which are found in soil or other materials contaminated with human feces (figure 1) [6,7]. The filariform larvae penetrate the skin and migrate hematogenously to the lungs where they penetrate into the alveolar air sacs. The larvae then ascend the tracheobronchial tree and are swallowed.

The larvae mature into adult worms that burrow into the mucosa of the duodenum and jejunum. Adult worms may live for up to five years. The adult female produces eggs, from which noninfectious larvae (rhabditiform larvae) develop within the lumen of the gastrointestinal tract. The rhabditiform larvae are generally passed in the feces. The cycle from dermal penetration to appearance of larvae in the stool requires approximately three to four weeks.

                      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2014. | This topic last updated: Feb 4, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Centers for Disease Control and Prevention. Notes from the field: Strongyloidiasis in a rural setting--Southeastern Kentucky, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:843.
  2. Centers for Disease Control and Prevention. Notes from the field: strongyloides infection among patients at a long-term care facility--Florida, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 62:844.
  3. Posey DL, Blackburn BG, Weinberg M, et al. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis 2007; 45:1310.
  4. Gyorkos TW, Genta RM, Viens P, MacLean JD. Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. Am J Epidemiol 1990; 132:257.
  5. Caruana SR, Kelly HA, Ngeow JY, et al. Undiagnosed and potentially lethal parasite infections among immigrants and refugees in Australia. J Travel Med 2006; 13:233.
  6. Schupf N, Ortiz M, Kapell D, et al. Prevalence of intestinal parasite infections among individuals with mental retardation in New York State. Ment Retard 1995; 33:84.
  7. Lindo JF, Robinson RD, Terry SI, et al. Age-prevalence and household clustering of Strongyloides stercoralis infection in Jamaica. Parasitology 1995; 110 ( Pt 1):97.
  8. Siddiqui AA, Genta RM, Berk SL. Chapter 111. In: Infectious Diseases - Principles, Practices and Pathogens, Guerrant RL, Walker DH, Weller PF (Eds), Churchhill-Livingstone Elsevier, Philadelphia 2006. p.1274.
  9. Chu E, Whitlock WL, Dietrich RA. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest 1990; 97:1475.
  10. Pelletier LL Jr, Baker CB, Gam AA, et al. Diagnosis and evaluation of treatment of chronic strongyloidiasis in ex-prisoners of war. J Infect Dis 1988; 157:573.
  11. Keiser PB, Nutman TB. Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev 2004; 17:208.
  12. Haque AK, Schnadig V, Rubin SA, Smith JH. Pathogenesis of human strongyloidiasis: autopsy and quantitative parasitological analysis. Mod Pathol 1994; 7:276.
  13. Nutman TB, Ottesen EA, Ieng S, et al. Eosinophilia in Southeast Asian refugees: evaluation at a referral center. J Infect Dis 1987; 155:309.
  14. Arsić-Arsenijević V, Dzamić A, Dzamić Z, et al. Fatal Strongyloides stercoralis infection in a young woman with lupus glomerulonephritis. J Nephrol 2005; 18:787.
  15. Robinson RD, Lindo JF, Neva FA, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994; 169:692.
  16. Mackey SL, Wagner KF. Dermatologic manifestations of parasitic diseases. Infect Dis Clin North Am 1994; 8:713.
  17. Meinking TL, Burkhart CN, Burkhart CG. Changing paradigms in parasitic infections: common dermatological helminthic infections and cutaneous myiasis. Clin Dermatol 2003; 21:407.
  18. Salluh JI, Bozza FA, Pinto TS, et al. Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: a pathognomonic feature of potentially lethal disease? Braz J Infect Dis 2005; 9:419.
  19. Reddy TS, Myers JW. Syndrome of inappropriate secretion of antidiuretic hormone and nonpalpable purpura in a woman with Strongyloides stercoralis hyperinfection. Am J Med Sci 2003; 325:288.
  20. Van Dellen RG, Maddox DE, Dutta EJ. Masqueraders of angioedema and urticaria. Ann Allergy Asthma Immunol 2002; 88:10.
  21. Mehta RK, Shah N, Scott DG, et al. Case 4. Chronic urticaria due to strongyloidiasis. Clin Exp Dermatol 2002; 27:84.
  22. Ly MN, Bethel SL, Usmani AS, Lambert DR. Cutaneous Strongyloides stercoralis infection: an unusual presentation. J Am Acad Dermatol 2003; 49:S157.
  23. Scowden EB, Schaffner W, Stone WJ. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) 1978; 57:527.
  24. Berkmen YM, Rabinowitz J. Gastrointestinal manifestations of the stongyloidiasis. Am J Roentgenol Radium Ther Nucl Med 1972; 115:306.
  25. Sen P, Gil C, Estrellas B, Middleton JR. Corticosteroid-induced asthma: a manifestation of limited hyperinfection syndrome due to Strongyloides stercoralis. South Med J 1995; 88:923.
  26. Wehner JH, Kirsch CM, Kagawa FT, et al. The prevalence and response to therapy of Strongyloides stercoralis in patients with asthma from endemic areas. Chest 1994; 106:762.
  27. Lin AL, Kessimian N, Benditt JO. Restrictive pulmonary disease due to interlobular septal fibrosis associated with disseminated infection by Strongyloides stercoralis. Am J Respir Crit Care Med 1995; 151:205.
  28. Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest 2005; 128:3681.
  29. Longworth DL, Weller PF. Hyperinfection syndrome with strongyloidiasis. In: Current Clinical Topics in Infectious Diseases, Remington JS, Swartz MN (Eds), McGraw-Hill, New York 1986. p.1.
  30. Woodring JH, Halfhill H 2nd, Reed JC. Pulmonary strongyloidiasis: clinical and imaging features. AJR Am J Roentgenol 1994; 162:537.
  31. Cebular S, Lee S, Tolaney P, Lutwick L. Community-acquired pneumonia in immunocompromised patients. Opportunistic infections to consider in differential diagnosis. Postgrad Med 2003; 113:65.
  32. Strazzella WD, Safirstein BH. Asthma due to parasitic infestation. N J Med 1989; 86:947.
  33. Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006; 25:14.
  34. Nwokolo C, Imohiosen EA. Strongyloidiasis of respiratory tract presenting as "asthma". Br Med J 1973; 2:153.
  35. Ghoshal UC, Ghoshal U, Jain M, et al. Strongyloides stercoralis infestation associated with septicemia due to intestinal transmural migration of bacteria. J Gastroenterol Hepatol 2002; 17:1331.
  36. Walker M, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis 2005; 40:1005.
  37. Schaeffer MW, Buell JF, Gupta M, et al. Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature. J Heart Lung Transplant 2004; 23:905.
  38. Adam M, Morgan O, Persaud C, Gibbs WN. Hyperinfection syndrome with Strongyloides stercoralis in malignant lymphoma. Br Med J 1973; 1:264.
  39. Cruz T, Reboucas G, Rocha H. Fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med 1966; 275:1093.
  40. Higenbottam TW, Heard BE. Opportunistic pulmonary strongyloidiasis complicating asthma treated with steroids. Thorax 1976; 31:226.
  41. Purtilo DT, Meyers WM, Connor DH. Fatal strongyloidiasis in immunosuppressed patients. Am J Med 1974; 56:488.
  42. Smith SB, Schwartzman M, Mencia LF, et al. Fatal disseminated strongyloidiasis presenting as acute abdominal distress in an urban child. J Pediatr 1977; 91:607.
  43. Stemmermann GN. Strongyloidiasis in migrants. Pathological and clinical considerations. Gastroenterology 1967; 53:59.
  44. Davidson RA. Infection due to Strongyloides stercoralis in patients with pulmonary disease. South Med J 1992; 85:28.
  45. Safdar A, Malathum K, Rodriguez SJ, et al. Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer 2004; 100:1531.
  46. Lemos LB, Qu Z, Laucirica R, Fred HL. Hyperinfection syndrome in strongyloidiasis: report of two cases. Ann Diagn Pathol 2003; 7:87.
  47. Hira PR, Al-Ali F, Shweiki HM, et al. Strongyloidiasis: challenges in diagnosis and management in non-endemic Kuwait. Ann Trop Med Parasitol 2004; 98:261.
  48. Orlent H, Crawley C, Cwynarski K, et al. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32:115.
  49. Centers for Disease Control and Prevention (CDC). Transmission of Strongyloides stercoralis through transplantation of solid organs--Pennsylvania, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:264.
  50. Ghosh K, Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg 2007; 101:1163.
  51. Concha R, Harrington W Jr, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol 2005; 39:203.
  52. Schad GA. Cyclosporine may eliminate the threat of overwhelming strongyloidiasis in immunosuppressed patients. J Infect Dis 1986; 153:178.
  53. Porto MA, Alcântara LM, Leal M, et al. Atypical clinical presentation of strongyloidiasis in a patient co-infected with human T cell lymphotrophic virus type I. Am J Trop Med Hyg 2005; 72:124.
  54. Satoh M, Kiyuna S, Shiroma Y, et al. Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1. Clin Exp Immunol 2003; 133:391.
  55. Rahim S, Drabu Y, Jarvis K, Melville D. Strongyloidiasis: a mistaken diagnosis and a fatal outcome in a patient with diarrhoea. Trans R Soc Trop Med Hyg 2005; 99:215.
  56. Carvalho EM, Da Fonseca Porto A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol 2004; 26:487.
  57. Plumelle Y, Pascaline N, Nguyen D, et al. Adult T-cell leukemia-lymphoma: a clinico-pathologic study of twenty-six patients from Martinique. Hematol Pathol 1993; 7:251.
  58. Montes M, Sanchez C, Verdonck K, et al. Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis 2009; 3:e456.
  59. Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 1994; 73:256.
  60. Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest 1993; 104:119.
  61. Kim AC, Lupatkin HC. Strongyloides stercoralis infection as a manifestation of immune restoration syndrome. Clin Infect Dis 2004; 39:439.
  62. Taylor CL, Subbarao V, Gayed S, Ustianowski AP. Immune reconstitution syndrome to Strongyloides stercoralis infection. AIDS 2007; 21:649.
  63. Brown M, Cartledge JD, Miller RF. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS 2006; 17:560.
  64. Viney ME, Brown M, Omoding NE, et al. Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis 2004; 190:2175.
  65. Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol 2005; 12:680.
  66. Sathiyasekaran M, Shibalan S. Intestinal strongyloidiasis and common variable immunodeficiency syndrome. Indian Pediatr 2005; 42:391.
  67. Boatright MD, Wang BW. Clinical infection with Strongyloides sterocoralis following etanercept use for rheumatoid arthritis. Arthritis Rheum 2005; 52:1336.
  68. Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. J Clin Rheumatol 2007; 13:150.
  69. Marty FM. Strongyloides hyperinfection syndrome and transplantation: a preventable, frequently fatal infection. Transpl Infect Dis 2009; 11:97.
  70. Vilela EG, Clemente WT, Mira RR, et al. Strongyloides stercoralis hyperinfection syndrome after liver transplantation: case report and literature review. Transpl Infect Dis 2009; 11:132.
  71. Valar C, Keitel E, Dal Prá RL, et al. Parasitic infection in renal transplant recipients. Transplant Proc 2007; 39:460.
  72. Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49:1411.
  73. Nuesch R, Zimmerli L, Stockli R, et al. Imported strongyloidosis: a longitudinal analysis of 31 cases. J Travel Med 2005; 12:80.
  74. Gill GV, Welch E, Bailey JW, et al. Chronic Strongyloides stercoralis infection in former British Far East prisoners of war. QJM 2004; 97:789.
  75. Johnston FH, Morris PS, Speare R, et al. Strongyloidiasis: a review of the evidence for Australian practitioners. Aust J Rural Health 2005; 13:247.
  76. Lim S, Katz K, Krajden S, et al. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 2004; 171:479.
  77. Agrawal V, Agarwal T, Ghoshal UC. Intestinal strongyloidiasis: a diagnosis frequently missed in the tropics. Trans R Soc Trop Med Hyg 2009; 103:242.
  78. Al-Hasan MN, McCormick M, Ribes JA. Invasive enteric infections in hospitalized patients with underlying strongyloidiasis. Am J Clin Pathol 2007; 128:622.
  79. Beal CB, Viens P, Grant RG, Hughes JM. A new technique for sampling duodenal contents: demonstration of upper small-bowel pathogens. Am J Trop Med Hyg 1970; 19:349.
  80. Boulware DR, Stauffer WM 3rd, Walker PF. Hypereosinophilic syndrome and mepolizumab. N Engl J Med 2008; 358:2839; author reply 2839.
  81. Rosenblatt JE. Clinical importance of adequately performed stool ova and parasite examinations. Clin Infect Dis 2006; 42:979.
  82. Hirata T, Nakamura H, Kinjo N, et al. Increased detection rate of Strongyloides stercoralis by repeated stool examinations using the agar plate culture method. Am J Trop Med Hyg 2007; 77:683.
  83. Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008; 10:105.
  84. Greiner K, Bettencourt J, Semolic C. Strongyloidiasis: a review and update by case example. Clin Lab Sci 2008; 21:82.
  85. Eveland LK, Kenney M, Yermakov V. Laboratory diagnosis of autoinfection in strongyloidiasis. Am J Clin Pathol 1975; 63:421.
  86. Schainberg L, Scheinberg MA. Recovery of Strongyloides stercoralis by bronchoalveolar lavage in a patient with acquired immunodeficiency syndrome. Am J Med 1989; 87:486.
  87. Smith B, Verghese A, Guiterrez C, et al. Pulmonary strongyloidiasis. Diagnosis by sputum gram stain. Am J Med 1985; 79:663.
  88. Williams J, Nunley D, Dralle W, et al. Diagnosis of pulmonary strongyloidiasis by bronchoalveolar lavage. Chest 1988; 94:643.
  89. Harris RA Jr, Musher DM, Fainstein V, et al. Disseminated strongyloidiasis. Diagnosis made by sputum examination. JAMA 1980; 244:65.
  90. Abdalla J, Saad M, Myers JW, Moorman JP. An elderly man with immunosuppression, shortness of breath, and eosinophilia. Clin Infect Dis 2005; 40:1464, 1535.
  91. ten Hove RJ, van Esbroeck M, Vervoort T, et al. Molecular diagnostics of intestinal parasites in returning travellers. Eur J Clin Microbiol Infect Dis 2009; 28:1045.
  92. Carroll SM, Karthigasu KT, Grove DI. Serodiagnosis of human strongyloidiasis by an enzyme-linked immunosorbent assay. Trans R Soc Trop Med Hyg 1981; 75:706.
  93. Neva FA, Gam AA, Burke J. Comparison of larval antigens in an enzyme-linked immunosorbent assay for strongyloidiasis in humans. J Infect Dis 1981; 144:427.
  94. Savage D, Foadi M, Haworth C, Grant A. Marked eosinophilia in an immunosuppressed patient with strongyloidiasis. J Intern Med 1994; 236:473.
  95. van Doorn HR, Koelewijn R, Hofwegen H, et al. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 2007; 45:438.
  96. Boscolo M, Gobbo M, Mantovani W, et al. Evaluation of an indirect immunofluorescence assay for strongyloidiasis as a tool for diagnosis and follow-up. Clin Vaccine Immunol 2007; 14:129.
  97. Ramanathan R, Burbelo PD, Groot S, et al. A luciferase immunoprecipitation systems assay enhances the sensitivity and specificity of diagnosis of Strongyloides stercoralis infection. J Infect Dis 2008; 198:444.
  98. Sreenivas DV, Kumar A, Kumar YR, et al. Intestinal strongyloidiasis--a rare opportunistic infection. Indian J Gastroenterol 1997; 16:105.
  99. Thompson BF, Fry LC, Wells CD, et al. The spectrum of GI strongyloidiasis: an endoscopic-pathologic study. Gastrointest Endosc 2004; 59:906.
  100. Overstreet K, Chen J, Rodriguez JW, Wiener G. Endoscopic and histopathologic findings of Strongyloides stercoralis infection in a patient with AIDS. Gastrointest Endosc 2003; 58:928.
  101. Qu Z, Kundu UR, Abadeer RA, Wanger A. Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential diagnosis. Hum Pathol 2009; 40:572.
  102. Drugs for Parasitic Infections, The Medical Letter http://medlet-best.securesites.com/html/parasitic_desc.htm (Accessed on August 17, 2009).
  103. Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, et al. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004; 5:2615.
  104. Zaha O, Hirata T, Kinjo F, et al. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother 2002; 8:94.
  105. Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996; 55:477.
  106. Archibald LK, Beeching NJ, Gill GV, et al. Albendazole is effective treatment for chronic strongyloidiasis. Q J Med 1993; 86:191.
  107. Muennig P, Pallin D, Challah C, Khan K. The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States. Epidemiol Infect 2004; 132:1055.
  108. Suputtamongkol Y, Kungpanichkul N, Silpasakorn S, Beeching NJ. Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis. Int J Antimicrob Agents 2008; 31:46.
  109. Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 2007; 41:1992.
  110. Pacanowski J, Santos MD, Roux A, et al. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report. Am J Trop Med Hyg 2005; 73:122.
  111. Leung V, Al-Rawahi GN, Grant J, et al. Case report: failure of subcutaneous ivermectin in treating Strongyloides hyperinfection. Am J Trop Med Hyg 2008; 79:853.
  112. Turner SA, Maclean JD, Fleckenstein L, Greenaway C. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg 2005; 73:911.
  113. Tarr PE, Miele PS, Peregoy KS, et al. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 2003; 68:453.
  114. Marty FM, Lowry CM, Rodriguez M, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis 2005; 41:e5.
  115. Salluh JI, Feres GA, Velasco E, et al. Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock. Intensive Care Med 2005; 31:1292.
  116. Miller MA, Church LW, Salgado CD. Strongyloides hyperinfection: a treatment dilemma. Am J Med Sci 2008; 336:358.
  117. Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health 2004; 35:531.
  118. Kobayashi J, Sato Y, Toma H, et al. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diagn Microbiol Infect Dis 1994; 18:19.
  119. Biggs BA, Caruana S, Mihrshahi S, et al. Management of chronic strongyloidiasis in immigrants and refugees: is serologic testing useful? Am J Trop Med Hyg 2009; 80:788.
  120. El Masry HZ, O'Donnell J. Fatal stongyloides hyperinfection in heart transplantation. J Heart Lung Transplant 2005; 24:1980.
  121. Terashima A, Alvarez H, Tello R, et al. Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection. Int J Infect Dis 2002; 6:28.
  122. Jeyamani R, Joseph AJ, Chacko A. Severe and treatment resistant strongyloidiasis--indicator of HTLV-I infection. Trop Gastroenterol 2007; 28:176.